Konstantinou K, Dunn KM. Sciatica: review of epidemiological studies and prevalence estimates. Spine (Phila Pa 1976) 2008; 33:2464–72.
Frymoyer JW. Back pain and sciatica. N Engl J Med. 1988;318:291–300.
Spijker-Huiges A, Groenhof F, Winters JC, et al. Radiating low back pain in general practice: incidence, prevalence, diagnosis, and long-term clinical course of illness. Scand J Prim Health Care. 2015;33:27–32.
Koes BW, van Tulder MW, Peul WC. Diagnosis and treatment of sciatica. BMJ. 2007;334:1313–7.
Tubach F, Beaute J, Leclerc A. Natural history and prognostic indicators of sciatica. J Clin Epidemiol. 2004;57:174–9.
Koes BW, van Tulder M, Lin CW, et al. An updated overview of clinical guidelines for the management of non-specific low back pain in primary care. Eur Spine J. 2010;19:2075–94.
Guyatt G, Oxman AD, Sultan S, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol. 2013;66:151–7.
Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res. 2004;4:38.
Ferreira M, Herbert R, Ferreira P, et al. The smallest worthwhile effect of non-steroidal anti-inflammatory drugs and physiotherapy for chronic low back pain. Pain. 2013;66:1397–404.
Ferreira ML, Herbert RD, Ferreira PH, et al. A critical review of methods used to determine the smallest worthwhile effect of interventions for low back pain. J Clin Epidemiol. 2012;65:253–61.
Giraudeau B, Rozenberg S, Valat JP. Assessment of the clinically relevant change in pain for patients with sciatica. Ann Rheum Dis. 2004;63:1180–1.
Saragiotto BT, Machado GC, Ferreira ML, et al. Paracetamol for low back pain. Cochrane Database Syst Rev 2016; 6:CD012230.
Machado GC, Maher CG, Ferreira PH, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350:h1225.
Serinken M, Eken C, Gungor F, et al. Comparison of intravenous morphine versus paracetamol in sciatica: a randomized placebo controlled trial. Acad Emerg Med. 2016;23:674–8.
van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low-back pain. Cochrane Database Syst Rev 2003;(2):CD004252.
Pinto RZ, Maher CG, Ferreira ML, et al. Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis. BMJ. 2012;344:e497.
Khoromi S, Cui L, Nackers L, et al. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain. 2007;130:66–75.
Yildirim K, Şışecıoğlu M, Karatay S, et al. The effectiveness of gabapentin in patients with chronic radiculopathy. Pain Clinic. 2003;15:213–8.
Baron R, Freynhagen R, Tolle TR, et al. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain. 2010;150:420–7.
Paeck T, Ferreira ML, Sun C, et al. Are older adults missing from low back pain clinical trials? A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66:1220–6.
Schofield D, Shrestha R, Passey M, et al. Chronic disease and labour force participation among older Australians. Med J Aust. 2008;189:447–50.
Costa Lda C, Maher CG, McAuley JH, et al. Prognosis for patients with chronic low back pain: inception cohort study. BMJ. 2009;339:b3829.
McLachlan AJ, Hilmer SN, Le Couteur DG. Variability in response to medicines in older people: phenotypic and genotypic factors. Clin Pharmacol Ther. 2009;85:431–3.
Hilmer S, McLachlan A, Le Couteur D. Clinical pharmacology in the geriatric patient. Fundam Clin Pharmacol. 2007;21:217–30.
Manias E, Claydon-Platt K, McColl GJ, et al. Managing complex medication regimens: perspectives of consumers with osteoarthritis and healthcare professionals. Ann Pharmacother. 2007;41:764–71.
Treharne GJ, Douglas KM, Iwaszko J, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskelet Care. 2007;5:175–90.
Vyas A, Pan X, Sambamoorthi U. Chronic condition clusters and polypharmacy among adults. Int J Fam Med. 2012;2012:193168.
Vincent A, Whipple MO, McAllister SJ, et al. A cross-sectional assessment of the prevalence of multiple chronic conditions and medication use in a sample of community-dwelling adults with fibromyalgia in Olmsted County, Minnesota. BMJ Open. 2015;5:e006681.
Chaparro LE, Wiffen PJ, Moore RA, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012;(7):CD008943. doi:10.1002/14651858.CD008943.pub2.
Blyth F, Rochat S, Cumming R, et al. Pain, frailty and comorbidity on older men: the CHAMP study. Pain. 2008;140:224–30.
Nobili A, Marengoni A, Tettamanti M, et al. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med. 2011;22:597–602.
Gore M, Sadosky A, Zlateva G, et al. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Am J Manag Care. 2010;16:S144–53.
Schmader KE, Baron R, Haanpaa ML, et al. Treatment considerations for elderly and frail patients with neuropathic pain. Mayo Clin Proc. 2010;85:S26–32.
Wallace JL. Polypharmacy of osteoarthritis: the perfect intestinal storm. Dig Dis Sci. 2013;58:3088–93.
Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85:86–8.
Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65:989–95.
Gnjidic D, Hilmer SN, Blyth FM, et al. High-risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91:521–8.
Abdel Shaheed C, Maher CG, Williams KA, et al. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med 2016;176(7):958–68.
Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315:1096–9.
Vitry AI, Zhang Y. Quality of Australian clinical guidelines and relevance to the care of older people with multiple comorbid conditions. Med J Aust. 2008;189:360–5.
Dumbreck S, Flynn A, Nairn M, et al. Drug-disease and drug–drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines. BMJ. 2015;350:h949.
Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716–24.
McLachlan AJ, Bath S, Naganathan V, et al. Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. Br J Clin Pharmacol. 2011;71:351–64.
Foy R, Leaman B, McCrorie C, et al. Prescribed opioids in primary care: cross-sectional and longitudinal analyses of influence of patient and practice characteristics. BMJ Open. 2016;6:e010276.
Steinman MA, Komaiko KD, Fung KZ, et al. Use of opioids and other analgesics by older adults in the United States, 1999–2010. Pain Med. 2015;16:319–27.
Hollingworth SA, Gray PD, Hall WD, et al. Opioid analgesic prescribing in Australia: a focus on gender and age. Pharmacoepidemiol Drug Saf. 2015;24:628–36.
Samuelsen PJ, Svendsen K, Wilsgaard T, et al. Persistent analgesic use and the association with chronic pain and other risk factors in the population-a longitudinal study from the Tromso Study and the Norwegian Prescription Database. Eur J Clin Pharmacol 2016;72(8):977–85.
Williams CM, Maher CG, Latimer J, et al. Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet. 2014;384:1586–96.
West NA, Dart RC. Prescription opioid exposures and adverse outcomes among older adults. Pharmacoepidemiol Drug Saf. 2016;25:539–44.
Lewis RA, Williams NH, Sutton AJ, et al. Comparative clinical effectiveness of management strategies for sciatica: systematic review and network meta-analyses. Spine J. 2015;15:1461–77.
Chaparro EL, Furlan AD, Deshpande A, et al. Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev 2013;(8):CD004959. doi:10.1002/14651858.CD004959.pub4.
Pinto RZ, Maher CG, Ferreira ML, et al. Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. Ann Int Med. 2012;157:865–77.
Urquhart DM, Hoving JL, Assendelft JJW, et al. Antidepressants for non-specific low back pain. Cochrane Database Syst Rev 2008;(1):CD001703. doi:10.1002/14651858.CD001703.pub3.
Abdi S, Datta S, Trescot AM, et al. Epidural steroids in the management of chronic spinal pain: a systematic review. Pain Physician. 2007;10:185–212.
Botwin KP, Gruber RD, Bouchlas CG, et al. Complications of fluoroscopically guided transforaminal lumbar epidural injections. Arch Phys Med Rehabil. 2000;81:1045–50.